Why Otsuka’s $1.2bn Transcend Therapeutics buyout could reshape PTSD drug development
Find out how Otsuka’s Transcend Therapeutics acquisition could reshape rapid-acting PTSD treatment development.
Pharma & Biotech
Medical Devices & Diagnostics
Wave Neuroscience FDA clearance puts EEG-guided PTSD treatment closer to clinical adoption
Find out how Wave Neuroscience’s MeRT FDA clearance could reshape biomarker-guided PTSD treatment and precision psychiatry.
Pharma & Biotech
Enveric Biosciences’ EB-003 push highlights the next battle in neuroplastogen drug development
Read how Enveric Biosciences’ EB-003 investor push reshapes CNS biotech risk, regulation and clinical strategy.
Pharma & Biotech
ReST Therapeutics wins FDA IND acceptance for RST-101 as early PTSD treatment strategy enters human testing
ReST Therapeutics’ RST-101 enters human testing for early PTSD. Find out why this IND acceptance could reshape trauma care.
Pharma & Biotech
Why electroCore, Inc.’s first PTSD patient enrollment could become a more important 2026 medtech catalyst than it first appears
electroCore, Inc. advances gammaCore in PTSD with first patient enrollment. Read why this 2026 medtech catalyst could matter more than it appears.
Medical Devices & Diagnostics
How electroCore, Inc. is strengthening the clinical case for bioelectronic medicine in trauma-related brain injury
electroCore, Inc.’s latest data could reshape bioelectronic medicine in trauma-related brain injury. Read what clinicians and industry watchers may track next.